Clearside Biomedical, Inc.

What they do

Clearside developed a proprietary SCS Microinjector for in-office, non-surgical injection of therapies into the suprachoroidal space to treat chorioretinal diseases. Its first product, XIPERE (triamcinolone acetonide injectable suspension), was FDA-approved in October 2021 for macular edema associated with uveitis. XIPERE is licensed to Bausch + Lomb in the U.S. and Canada and to Arctic Vision in Asia Pacific (excluding Japan). The company's lead internal pipeline candidate is CLS-AX.

Revenue drivers

• License and collaboration revenue — All revenue to date comes from upfront and milestone payments under license agreements, including the Bausch + Lomb and Arctic Vision arrangements; Clearside has never recorded product sales of XIPERE.
• XIPERE royalties/milestones (indirect) — As XIPERE is commercialized by licensees, Clearside could receive milestone and royalty payments, but no product revenue has been generated.
• SCS platform partnerships — The company seeks collaborations with other ophthalmic developers to use its SCS injection technology, which could generate future license or milestone revenue.
• CLS-AX pipeline (pre-revenue) — CLS-AX is in development for suprachoroidal administration; it has not generated revenue and would require regulatory approval and commercialization.

Recent performance

Annual revenue has been volatile: $7.9M in 2020, $29.6M in 2021, $1.3M in 2022, $8.2M in 2023, and $1.7M in 2024. Net losses were $32.5M in 2023 and $34.4M in 2024, with an accumulated deficit of $355.3M as of December 31, 2024. For the nine months ended September 30, 2025, net loss was $18.7M versus $27.0M a year earlier. Quarterly revenue was $2.3M in Q1 2025, $492K in Q2 2025, and $201K in Q3 2025. As of September 30, 2025, total assets were $11.6M, total liabilities $65.6M, and shareholders' equity was negative $54.0M, with $6.8M in cash and equivalents.

Strategy

In July 2025, Clearside announced a strategic review to explore alternatives including sale, license, monetization, or divestiture of assets, as well as collaboration, merger, or other transactions, retaining Piper Sandler as advisor. Management stated that without a strategic alternative, it would need to take additional actions to fund operations or possibly file for bankruptcy. Previously, the company focused on developing CLS-AX and its SCS platform. The company has financed operations primarily through equity offerings, warrants, convertible notes, and loans.

Risks

• Going concern — The 10-K states that factors raise substantial doubt about the company's ability to continue as a going concern, and it expects resources to fund operations only into Q4 2025.
• Bankruptcy and delisting — 8-K events since November 2025 include bankruptcy or receivership, delisting notices, and listing-rule failures, and the ticker now appears as CLSDQ.
• No product revenue — Clearside has never generated revenue from XIPERE sales and relies entirely on license and milestone payments, which have been highly variable.
• Capital needs — The company will require additional capital to complete clinical development of CLS-AX, and it recorded a net loss of $34.4M in 2024.

Outlook

Management is pursuing a strategic review process with Piper Sandler to maximize stockholder value through potential asset sales, licenses, monetization, partnerships, or mergers. If no strategic alternative is available, the company will need to take additional actions to fund operations or may be forced to file for bankruptcy. The 10-K states that current resources are only sufficient to fund planned operations into the fourth quarter of 2025. Clinical development of CLS-AX and further pipeline work will require substantial additional capital.